Clinical Trial Update: Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update assesses the safety of combining SBRT with an anti-PD-1 therapy (nivolumab) and an anti-IL-8 agent. The study targets patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Unresectable Solid Tumors

Drugs mentioned

• Anti-IL-8 (anti-IL-8)
• nivolumab (nivolumab)

Snippet

Sponsor: Yana Najjar | Conditions: Melanoma, Unresectable Solid Tumors | Phase 1 | Status: RECRUITING